ArticleNanomaterials (Basel, Switzerland)2018
Implementation of Safe-by-Design for Nanomaterial Development and Safe Innovation: Why We Need a Comprehensive Approach.
Article in Nanomaterials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Basic Substances and Nanotechnology: Bridging Sustainability and Innovation for Fungal Disease Management in Plants.Plants (Basel, Switzerland) · 2026Review
- Nanoparticle Applications in Plant Biotechnology: A Comprehensive Review.Plants (Basel, Switzerland) · 2026Review
- Nanotoxicity of Porous Silica Nanoparticles: Physicochemical Properties and Mechanistic Cellular Endpoints.Nanomaterials (Basel, Switzerland) · 2025Review
- Hazard screening of colloidal silica nanomaterials with varying degrees of silane surface functionalization: a safe-by-design case study.Particle and fibre toxicology · 2025Article
- Design Considerations for Organ-Selective Nanoparticles.ACS nano · 2025Review
- Bionanotechnology: A Paradigm for Advancing Environmental Sustainability.Indian journal of microbiology · 2025Article
- Going digital to boost safe and sustainable materials innovation markets. The digital safe-and-sustainability-by-design innovation approach of the PINK project.Computational and structural biotechnology journal · 2025Article
- A roadmap towards safe and sustainable by design nanotechnology: Implementation for nano-silver-based antimicrobial textile coatings production by ASINA project.Computational and structural biotechnology journal · 2024Article
- Advancing titanium dioxide coated photocatalytic depolluting surfaces: Leveraging ASINA's roadmap for safer and sustainable solutions.Computational and structural biotechnology journal · 2024Article
- Article
- Exploring the relationships between physiochemical properties of nanoparticles and cell damage to combat cancer growth using simple periodic table-based descriptors.Beilstein journal of nanotechnology · 2024Article
- Knowledge, Information, and Data Readiness Levels (KaRLs) for Risk Assessment, Communication, and Governance of Nano-, New, and Other Advanced Materials.Global challenges (Hoboken, NJ) · 2023Article
- Lecithin and Chitosan as Building Blocks in Anti-Pharmaceuticals (Basel, Switzerland) · 2023Article
- The Effect of Curcumin-Loaded Glucan Nanoparticles on Immune Cells: Size as a Critical Quality Attribute.Pharmaceutics · 2023Article
- Review
- Physico-Chemical Transformation and Toxicity of Multi-Shell InP Quantum Dots under Simulated Sunlight Irradiation, in an Environmentally Realistic Scenario.Nanomaterials (Basel, Switzerland) · 2022Article
- Effects of Carbon Nanomaterials andPharmaceutics · 2022Review
- Quantifying Emission Factors and Setting Conditions of Use According to ECHA Chapter R.14 for a Spray Process Designed for Nanocoatings-A Case Study.Nanomaterials (Basel, Switzerland) · 2022Article
- Safe- and sustainable-by-design: The case of Smart Nanomaterials. A perspective based on a European workshop.Regulatory toxicology and pharmacology : RTP · 2022Article
- Risk Analysis and Technology Assessment of Emerging (Gd,Ce)Nanomaterials (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Manufactured nanomaterials (MNMs) are regarded as key components of innovations in various fields with high potential impact (e.g., energy generation and storage, electronics, photonics, diagnostics, theranostics, or drug delivery agents). Widespread use of MNMs raises concerns about their safety for humans and the environment, possibly limiting the impact of the nanotechnology-based innovation. The development of safe MNMs and nanoproducts has to result in a safe as well as functional material or product. Its safe use, and disposal at the end of its life cycle must be taken into account too. However, not all MNMs are similarly useful for all applications, some might bear a higher hazard potential than others, and use scenarios could lead to different exposure probabilities. To improve both safety and efficacy of nanotechnology, we think that a new proactive approach is necessary, based on pre-regulatory safety assessment and dialogue between stakeholders. On the basis of the work carried out in different European Union (EU) initiatives, developing and integrating MNMs Safe-by-Design and Trusted Environments (NANoREG, ProSafe, and NanoReg2), we present our point of view here. This concept, when fully developed, will allow for cost effective industrial innovation, and an exchange of key information between regulators and innovators. Regulators are thus informed about incoming innovations in good time, supporting a proactive regulatory action. The final goal is to contribute to the nanotechnology governance, having faster, cheaper, effective, and safer nano-products on the market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.